Diminishing returns from ultra-hypofractionated radiation therapy for prostate cancer

More than a decade of randomized controlled trials in prostate cancer have established a positive radiation dose response at moderate doses and a consistently low α/β ratio in the linear quadratic model for moderate hypofractionation. The recently published large randomized trial of ultra-hypofractionated prostate cancer radiotherapy adds substantially to our current knowledge of dose-response and fractionation sensitivity.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research

Related Links:

ConclusionsFunctional outcomes after treatment for localized prostate cancer can be predicted at the time of diagnosis based on age, race, PSA, biopsy grade, baseline function, and a general question regarding overall health. Providers and patients can use this prediction tool to inform shared decision making.Patient summaryIn this report, we studied patient-reported sexual, urinary, hormonal, and bowel function through 5 yr after treatment with radical prostatectomy, radiation therapy, or active surveillance for localized prostate cancer. We developed a web-based predictive tool that can be used to predict one’s o...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsThe RT techniques for the treatment of PCa are statistically equivalent with respect to the bRFS rate. This paper confirms that the bRFS rates of Mexican PCa patients who were treated with conventional vs. hypofractionated schemes do not differ significantly.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Thousands of men across the world have participated in randomized clinical trials testing the role of hormone therapy in the curative treatment of localized, high-risk prostate cancer. Over several decades, we have established that long-term hormone therapy improves survival, even in the setting of dose-escalated external beam radiation therapy (EBRT).1 Recently reported clinical trials suggest that for some men 18 months of hormone therapy may be a suitable duration that balances treatment efficacy with quality-of-life preservation.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Editorial Source Type: research
CONCLUSIONS: CCIC is an effective means of treating refractory bladder neck contractures and/or urinary incontinence. While morbidity rates are high, subjective patient satisfaction is high. PMID: 32065865 [PubMed - in process]
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research
ConclusionThe success rate and functional outcome after BMGU for radiation-induced strictures were reasonable. However, compared to existing long-term data on non-irradiated patients, the outcome is impaired and patients should be counseled accordingly.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
iot S, Pasquier D Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80% of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial prostate specific antigen serum concentration value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controvers...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Condition:   Metastatic Prostate Cancer Interventions:   Drug: Atezolizumab;   Drug: Abiraterone;   Drug: Prednisone;   Drug: Lupron Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractPurposeThis retrospective study aims at investigating the effects of moderately hypofractionated radiation therapy (HRT) on acute and late toxicities as well as on early biochemical control and therapeutic efficiency compared to conventional radiation therapy (CRT) in prostate cancer.Patients and methodsWe analyzed 55  HRT patients irradiated with the total dose of 60 Gy in 20 fractions delivered over 4 weeks. These patients were compared to a control group of 55 patients who received CRT with a total of
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. The purpose of this study was to determine the maximum tolerated dose for concurrent cabazitaxel with androgen deprivation and intensity modulated radiation therapy in men with high-risk prostate cancer.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Physics | Prostate Cancer | Radiation Therapy | Radiology